1313725-88-0

Basic information

• Product Name: Volitinib
• Synonyms: AZD6094,Volitinib, HMPL-504, Savolitinib;1-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine;(S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine;Volitinib;Savolitinib;HMPL-504(AZD6094, Volitinib);EOS-60799;AZD-6094)
• CAS NO: 1313725-88-0
• Molecular Formula: C17H15N9
• Molecular Weight: 345.3613
• Product Categories: API
• Mol File: 1313725-88-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 5.67±0.50(Predicted)
• CAS DataBase Reference: Volitinib(CAS DataBase Reference)
• NIST Chemistry Reference: Volitinib(1313725-88-0)
• EPA Substance Registry System: Volitinib(1313725-88-0)

Safety Data

• Hazardous Substances Data: 1313725-88-0(Hazardous Substances Data)

Usage

Uses

Savolitinib is a potent and highly selective c-Met inhibitor. Savoltinib demonstrated anti-tumor efficacy in a panel of cMet-dysregulated gastric cancer PDX models. Savolitinib also demonstrated good antitmuor activities.

Upstream product

• 139022-25-6 imidazo[1,2-a]pyridine-6-carboxylic acid 
• 1313726-20-3 imidazo[1,2-a]pyridine-6-carboxylic acid methoxy(methyl)amide 
• 944905-12-8 1-(imidazo[1,2-a]pyridin-6-yl)ethanone 
• 3167-49-5 6-aminonicotinic acid 
• 761446-44-0 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1259603-82-1 (1S)-1-imidazo[1,2-a]pyridin-6-ylethanamine 
• 136117-69-6 methyl 6-imidazo<1,2-a>pyridinecarboxylate 
• 36052-24-1 methyl 6-aminonicotinoate 
• 1270475-03-0 1-(imidazo[1,2-a]pyridin-6-yl)ethanamine 
• 1313723-58-8 1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine 

Relevant articles and documents

Process Design and Optimization in the Pharmaceutical Industry: A Suzuki-Miyaura Procedure for the Synthesis of Savolitinib

A multidisciplinary approach covering synthetic, physical, and analytical chemistry, high-throughput experimentation and experimental design, process engineering, and solid-state chemistry is used to develop a large-scale (kilomole) Suzuki-Miyaura process. Working against clear criteria and targets, a full process investigation and optimization package is described highlighting how and why key decisions are made in the development of large-scale pharmaceutical processes.

IMPROVED METHOD FOR THE MANUFACTURE OF 3-[(1S)-1-IMIDAZO[1,2-A]PYRIDIN-6-YLETHYL]-5-(1-METHYLPYRAZOL-4-YL)TRIAZOLO[4,5-B]PYRAZINE AND POLYMORPHIC FORMS THEREOF

This specification generally relates to an improved method for the manufacture of 3-[(lS)-l -imidazo[ 1,2-a]pyridin-6-ylethyl]-5-(l-methylpyrazol-4-yl)triazolo[4,5- bjpyrazine (I), or pharmaceutically acceptable salts thereof; polymorphic forms thereof; and intermediates useful in the manufacture of such compounds and salts thereof. Formula (I).

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.